RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology.

Autor: Petricoin E 3rd; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Wulfkuhle J; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Howard M; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Pierobon M; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Espina V; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Luchini A; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Liotta LA; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. liotta.lance@gmail.com.
Jazyk: angličtina
Zdroj: Advances in experimental medicine and biology [Adv Exp Med Biol] 2019; Vol. 1188, pp. 1-19.
DOI: 10.1007/978-981-32-9755-5_1
Abstrakt: RPPA technology has graduated from a research tool to an essential component of clinical drug discovery research and personalized medicine. Next generations of RPPA technology will be a single clinical instrument that integrates all the steps of the workflow.
Databáze: MEDLINE